MS SB2527

Expands eligibility for investigational drugs, biological products, and devices to patients with debilitating disabilities or life-threatening illnesses that have not responded to currently approved treatments, in addition to terminal illness patients.

Revises definition of "investigational drug, biological product or device" to include treatments described in FDA/NIH-approved protocols or approved by institutional review boards that have completed phase one clinical trials and show prior evidence of safe usage in humans.

Provides tort immunity to manufacturers, distributors, prescribers, dispensers, and hospital owners from liability for investigational drug use, except in cases of gross negligence or willful misconduct.

Clarifies that health plans, third-party administrators, and providers are not obligated to pay for investigational drug costs or consequent care, and are not liable for outstanding debt related to such treatment.

Prohibits state agencies and regulatory boards from revoking or failing to renew physician or pharmacist licenses based solely on recommending investigational drug access to eligible patients.